Key clinical point: Twice-daily, extended-release arbaclofen effectively reduces MS-related spasticity.
Major finding: Mean change in TNmAS-MAL was −2.90 with arbaclofen and −1.95 with placebo.
Study details: A multicenter, double-blind, parallel-group study of 341 adults with MS and spasticity.
Disclosures: The study did not have funding support. Dr. Kantor reported having received consulting fees from AbbVie, Actelion, Bayer, Biogen, Celgene, EMD Serono, Genentech/Roche, Mylan, Novartis, Osmotica, and Sanofi Genzyme.
Citation: Kantor D et al. CMSC 2019, Abstract SXM07.